林西替尼通过抑制人甲状腺细胞中促甲状腺激素与胰岛素样生长因子1受体的串扰减少促甲状腺激素诱导的甲状腺激素合成:体外及小鼠体内研究
研究在人甲状腺原代细胞和小鼠中探讨IGF-1R激酶抑制剂林西替尼对TSH诱导的甲状腺过氧化物酶(TPO)和甲状腺球蛋白(TG)表达及游离甲状腺素(fT4)的影响。林西替尼抑制bTSH诱导的hTPO mRNA上调61.5%、hTPO蛋白42.4%,并抑制分泌型和细胞相关hTG蛋白分别50.1%和42.2%,但不影响hTG mRNA;小鼠中mTpo mRNA降低31.5%,fT4水平在基础及bTSH处理条件下均下降。作者建议在给人使用林西替尼(例如治疗TED)时监测甲状腺功能。
要点
- 林西替尼抑制bTSH诱导的人甲状腺细胞hTPO mRNA上调61.5%、hTPO蛋白42.4%。
- 林西替尼不影响hTG mRNA,但通过抑制翻译使分泌型和细胞相关hTG蛋白分别降低50.1%和42.2%。
- 小鼠中林西替尼使mTpo mRNA降低31.5%,并在基础及bTSH处理条件下降低fT4水平。
核心结论
- IGF-1R拮抗剂林西替尼抑制bTSH刺激的人甲状腺原代细胞hTG和hTPO蛋白表达以及小鼠fT4水平。
- 作者建议在给人使用林西替尼时(例如用于治疗TED)监测甲状腺功能。
研究设计与样本
- 体外研究:人甲状腺原代细胞培养,检测TPO和TG mRNA及蛋白。
- 体内研究:小鼠连续3天给予林西替尼,随后腹腔注射牛TSH,3小时后采血检测甲状腺mTpo、mTg mRNA及fT4。
主要发现
- 人甲状腺原代细胞中,林西替尼抑制bTSH诱导的hTPO mRNA上调61.5%,hTPO蛋白抑制42.4%。
- 林西替尼对hTG mRNA无影响,但使分泌型和细胞相关hTG蛋白分别降低50.1%和42.2%,通过抑制hTG mRNA翻译实现。
- 小鼠甲状腺中,林西替尼使mTpo mRNA降低31.5%,对mTg mRNA无影响。
- 小鼠中林西替尼在基础(内源性mTSH水平)和bTSH处理条件下均降低fT4水平。
临床怎么用
- 作者建议在给人使用林西替尼时(例如用于治疗TED)监测甲状腺功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) have been shown to crosstalk in primary cultures of human thyrocytes (hThyros) and Graves' orbital fibroblasts. The phenomenon of TSHR/IGF-1R crosstalk has been largely studied in the pathogenesis of thyroid eye disease (TED) in human orbital fibroblasts. Here, we investigated the effects of inhibiting the IGF-1R-mediated contribution to crosstalk by linsitinib (Lins), a small-molecule IGF-1R kinase inhibitor, on TSH-induced regulation of thyroperoxidase (TPO) and thyroglobulin (TG) mRNAs and proteins in hThyros in vitro, and on TPO and TG mRNAs and free thyroxine (fT4) levels in vivo in mice. Methods: Steady-state levels of mRNAs of TPO and TG in hThyros in vitro and mouse thyroid glands were measured by RT-qPCR. Human TG (hTG) and human TPO (hTPO) proteins in human thyroid cell cultures were measured by Western blot or ELISA. Translation rates of hTG were quantified by stable isotope labeling by amino acids method (SILAC). Thyroidal mouse Tpo (mTpo) and Tg (mTg) mRNAs and fT4 in mice were assessed after Lins administration on 3 consecutive days followed by an intraperitoneal dose of bovine TSH (bTSH) 3 hours prior to drawing blood. Results: In primary cultures of hThyros, Lins inhibited bTSH-induced upregulation of hTPO mRNA by 61.5%, and hTPO protein was inhibited by 42.4%. There was no effect of Lins on hTG mRNA, but Lins inhibited the upregulation of secreted and cell-associated hTG protein by 50.1% and 42.2%, respectively, by inhibiting hTG mRNA translation. mTpo mRNA measured in thyroid glands after treatment with Lins was reduced by 31.5%. There was no effect of Lins on mTg mRNA, however, Lins decreased fT4 levels in mice under basal (endogenous mTSH levels) and bTSH-treated conditions. Conclusions: The IGF-1R antagonist Lins inhibited bTSH-stimulated hTG and hTPO protein expression in primary cultures of hThyros and fT4 levels in mice. We suggest that thyroid function studies be monitored when Lins is administered to humans, for example, if it is used to treat TED.
引用
- Boutin A, Eliseeva E, Templin S, et al. Linsitinib Decreases Thyrotropin-Induced Thyroid Hormone Synthesis by Inhibiting Crosstalk Between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors in Human Thyrocytes In Vitro and In Vivo in Mice. Thyroid. 2024. PMID: 39718934. doi:10.1089/thy.2024.0393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。